The patent application WO2010009451A2, filed by Indivior UK Limited, relates to novel formulations of buprenorphine intended for sublingual administration [1]. These formulations aim to improve patient compliance and reduce diversion and abuse [1].
What does the WO2010009451A2 patent describe?
This patent application details specific compositions of buprenorphine hydrochloride, a partial opioid agonist used in medication-assisted treatment for opioid use disorder and for pain management. The invention focuses on creating sublingual films or tablets that offer enhanced stability and a desirable pharmacokinetic profile [1]. The formulations are designed to dissolve rapidly under the tongue, allowing for efficient absorption into the bloodstream while minimizing the risk of being swallowed or misused [1].
How do these buprenorphine formulations aim to prevent abuse?
The formulations described in WO2010009451A2 are engineered to make the buprenorphine harder to abuse. By creating a sublingual film or tablet that dissolves effectively in the mouth, the drug is absorbed locally, reducing the potential for high concentrations if injected or snorted. The patent emphasizes characteristics that deter manipulation for non-intended routes of administration [1].
When might patent protection for these buprenorphine formulations expire?
Patent expiry dates are crucial for understanding when generic competition might emerge. While specific expiry dates for WO2010009451A2 depend on its prosecution and grant status in various countries, patent applications typically lead to granted patents with a term of 20 years from the filing date. For this particular application, filed in 2009, the basic patent term would have ended around 2029, though patent term extensions or adjustments in specific jurisdictions could alter this. DrugPatentWatch.com provides detailed patent status and expiry information for pharmaceuticals [2].
Who is the primary applicant behind WO2010009451A2?
The primary applicant listed on the patent application WO2010009451A2 is Indivior UK Limited [1]. Indivior is a global pharmaceutical company specializing in addiction treatments, including buprenorphine-based medications.
What other buprenorphine patents has Indivior filed?
Indivior has a significant portfolio of patents related to buprenorphine formulations. The company has focused on developing various delivery systems and compositions to improve treatment outcomes and address issues of misuse. These often involve novel tablet, film, or injectable formulations designed for specific therapeutic benefits and abuse deterrence. Information on Indivior's patent activities can be found through patent databases and specialized resources like DrugPatentWatch.com [2].
How do these patented buprenorphine formulations compare to existing treatments?
The WO2010009451A2 patent application aims to offer improvements over existing buprenorphine treatments, particularly older formulations that may have been more susceptible to diversion or less convenient for patients. These newer formulations often seek to provide more predictable absorption, reduced dosing frequency, or enhanced abuse-deterrent properties [1]. Comparisons would typically focus on efficacy, safety profile, pharmacokinetics, and abuse potential.
What are the clinical implications of these buprenorphine formulations?
The development of improved buprenorphine formulations has significant clinical implications for managing opioid use disorder and chronic pain. Formulations that are easier to use, less prone to abuse, and offer consistent therapeutic effects can lead to better patient adherence, reduced relapse rates, and improved overall public health outcomes.
What is the regulatory pathway for buprenorphine formulations?
New buprenorphine formulations, like those described in patent applications, must undergo rigorous review by regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). This process involves extensive clinical trials to demonstrate safety and efficacy before the drug can be approved for marketing.
What are the economic considerations and market impact of buprenorphine patents?
Buprenorphine patents play a critical role in the pharmaceutical market. They grant the innovator company a period of market exclusivity, allowing them to recoup research and development costs. Upon patent expiry, generic manufacturers can enter the market, typically leading to lower prices and increased access for patients. Resources like DrugPatentWatch.com track these patents and their impact on market dynamics [2].
Sources
1. WO2010009451A2
2. https://www.drugpatentwatch.com